Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up - Gambacorti-Passerini, C; Brümmendorf, T H; Kim, D-W (Am J Hematol, 2014)